Fondaparinux

證據等級: L5

預測適應症: 10 個

Fondaparinux: From Anticoagulation to Heparin-Induced Thrombocytopenia (Primary Platelet Release Disorder)

One-Sentence Summary

Fondaparinux is a synthetic Factor Xa inhibitor anticoagulant (brand name Arixtra), typically used for prevention and treatment of venous thromboembolic events. The TxGNN model predicts it may be effective for primary release disorder of platelets — an ontology term that, based on the supporting evidence, corresponds clinically to heparin-induced thrombocytopenia (HIT) — with a 93.06% TxGNN confidence score, currently supported by 2 clinical trials and 2 literature references.

Quick Overview

Item	Content
Original Indication	Not documented in this evidence pack (drug-level indication and MOA fields are marked as data gaps; Fondaparinux’s general clinical use is as an anticoagulant)
Predicted New Indication	Primary release disorder of platelets (clinically interpreted as Heparin-Induced Thrombocytopenia, HIT)
TxGNN Prediction Score	93.06%
Evidence Level	L2
Australia Market Status	Not marketed (0 local entries)
Number of ARTG Entries	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data for Fondaparinux is not available in this evidence pack (flagged as data gap DG002, pending a DrugBank API query). Based on the mechanistic rationale documented for this specific prediction, Fondaparinux is a synthetic pentasaccharide that selectively inhibits Factor Xa via antithrombin III. Critically, unlike unfractionated or low-molecular-weight heparin, it does not form immunogenic complexes with platelet factor 4 (PF4).

This distinguishing feature is precisely why Fondaparinux is relevant to HIT: because HIT is driven by antibodies against PF4/heparin complexes that trigger pathological platelet activation and consumption (a form of platelet release disorder), a non-cross-reactive anticoagulant offers a mechanistically sound alternative once heparin must be withdrawn. This off-label use is already recognised in international guidance (e.g., ASH 2018), which lends external plausibility to the TxGNN prediction beyond the model score alone.

One caveat: the TxGNN disease label “primary release disorder of platelets” is a broad ontology term, and the evidence pack notes it needs confirmation that it precisely maps to HIT rather than other platelet release defects (e.g., δ-storage pool disease), where anticoagulation would not be an appropriate treatment. Of the 10 candidates TxGNN generated for this drug, this is the only one with clinical-trial and literature support (L2); the remaining nine are L5 (model-prediction only), and several carry a theoretical bleeding-risk concern given Fondaparinux’s anticoagulant mechanism.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrolment	Key Findings
NCT00911300	Phase 2	Completed	349	International multicentre, randomised, open-label pilot comparing Fondaparinux vs. heparin/vitamin-K antagonists for anticoagulation around electrical cardioversion; assesses thromboembolic and bleeding event prevention.
NCT01178333	N/A (retrospective)	Completed	668	Retrospective analysis of patients with a positive heparin PF-4 antibody test (HIT-RADIO), examining incidence and outcomes (platelet counts, thrombosis, amputation, death) — supportive epidemiological context rather than an interventional efficacy trial.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
28646118	2017	Review	Blood	Review of direct oral anticoagulants (DOACs, e.g. rivaroxaban) for treatment of serologically confirmed HIT, including the Hamilton clinical experience and literature synthesis — relevant background on non-heparin anticoagulant strategies for HIT, though focused on DOACs rather than Fondaparinux specifically.
30018843	2017	Case report	Journal of the Advanced Practitioner in Oncology	Abstract concerns palliative chemotherapy decision-making in a patient with metastatic adenocarcinoma of unknown origin; content does not appear related to Fondaparinux or platelet release disorders — likely a search/mapping artefact and should be treated with low confidence.

Australia Market Information

Fondaparinux currently has no ARTG entries and is not marketed in Australia, so no local product listing or approved-indication text is available in this evidence pack.

Safety Considerations

No key warnings, contraindications, or drug-interaction data were returned for this evidence pack (TFDA/product-label warnings and contraindications are flagged as a Blocking data gap — DG001 — which prevents the initial safety review stage; the DDI query also returned no results). Because Fondaparinux is not currently registered locally, there is no TGA/TFDA-approved Product Information to reference directly — safety assessment should draw on the overseas-approved label (e.g., Arixtra PI from a reference regulator) until local documentation is obtained.

Conclusion and Next Steps

Decision: Hold

Rationale: The mechanistic case and supporting Phase 2/retrospective evidence (L2) for using Fondaparinux in HIT are reasonably strong and consistent with existing international off-label guidance. However, a Blocking data gap on safety warnings/contraindications means the candidate cannot yet pass initial safety screening (S1), and the drug is not currently marketed or registered in Australia.

To proceed, the following is needed:

TFDA/overseas product-label warnings and contraindications (DG001 — blocking; source: TFDA official site, PI PDF parsing)
Confirmed mechanism of action from DrugBank (DG002; source: DrugBank API)
Confirmation that “primary release disorder of platelets” precisely corresponds to HIT rather than an unrelated platelet release defect
Local registration pathway assessment, since Fondaparinux currently has zero ARTG entries in Australia
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.